It's incredibly common in veterinary medicine in the US.
Veterinary pharmaceuticals are oftentimes (though not always) manufactured in the same plants. Sometimes the inactive ingredients are not safe for human consumption, so that doesn't mean that you can always just take veterinary drugs safely, but sometimes (particularly in the case of antibiotics), they are literally manufactured on the same lines, and are simply packaged and distributed differently.
Given the massive difference in price between albendazole for humans and albendazole for animals, I'm willing to bet that this is another attempt at market segmentation (which we already know is rampant in the US pharmaceutical industry - that's how they make their global profits!), rather than a real necessity of the scale.
Unless it's okay because we can rationalize it as "it helps make the product accessible to poorer countries".
Want to lower drug prices? Enact tort reform.
I tried to google it myself but didn't find anything clear on the matter.
So apparently this medicine is used for treating parasitic worm infections, which I imagine is a vanishingly small market in the United States. That means that the costs of tooling up to produce the drug (and producing it to the standards of safety and purity demanded of any medicine produced in the U.S.) must be amortized over a tiny population of customers.
To make a comparison: a commercial Common Lisp IDE runs nearly $1,000 for a hobbyist edition, while you can get professional versions Clion or Jetbrains for $100-400. But there's no patent or other protections limiting competition in the development tools industry. It's simply the economics of making a product that caters to a tiny niche of potential customers.